Glaxosmithkline Pharmaceuticals Ltd vs Vineet Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2335 as of 30 Apr 15:30 . The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 yearsThe P/E Ratio of Vineet Laboratories Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 yearsThe Market Cap of Vineet Laboratories Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 1091 crore as compare to the Sep '25 revenue of ₹ 1016 crore. This represent the growth of 7.4% The revenue of Vineet Laboratories Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 421.44 crore as compare to the Sep '25 ebitda of ₹ 371.94 crore. This represent the growth of 13.31% The ebitda of Vineet Laboratories Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 295.62 crore over 7 quarters. This represents a CAGR of 31.80% The net profit of Vineet Laboratories Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 99.54 % on March 2025 . This represents a CAGR of -6.88% over 5 yearsThe Dividend Payout of Vineet Laboratories Ltd changed from 13.89 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years .

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

About Vineet Laboratories Ltd

Vineet Laboratories Limited, formerly known as Ortin Laboratories Limited is a manufacturing company of intermediates useful for the manufacture of active pharmaceutical ingredients.
The Company was incorporated on 10 November 2016 and operates in the business of in the manufacture of Drug Intermediates & Bulk Dugs.
The name of the Company changed to Vineet Laboratories Limited, on account of demerger in December, 2020. The production unit located at Malkapur Village, Yadadri- Bhuvanagiri District in Telangana State, India, is a multipurpose facility well equipped with stainless steel and glass-lined reactors with total volume of 230KL, of different volumes to suit any batch size.
Special provisions are made to carry out reactions at very low temperature (up to -100°C).
The Company is also specialized in manufacturing and handling pyrophoric chemicals like n-Butyl Lithium.

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and Vineet Laboratories Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or Vineet Laboratories Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 39,566 Cr while Market cap of Vineet Laboratories Ltd is 73 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and Vineet Laboratories Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and Vineet Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and Vineet Laboratories Ltd?

As of May 3, 2026, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2335.6. On the other hand, Vineet Laboratories Ltd stock price is INR ₹38.1.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Vineet Laboratories Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Vineet Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.